Concerns Rise as Novo Nordisk's Cagrisema Falls Short in Diabetes Studies

Shares of Novo Nordisk took a hit following the release of clinical results for its diabetes treatment, Cagrisema. Investors expressed concern as the findings didn't quite meet expectations, leading to a noticeable drop in stock value.

Continue reading